Integra Lifesciences Holdings Corp (NASDAQ:IART) has received a consensus recommendation of “Hold” from the eighteen analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $60.80.

Several equities analysts have issued reports on IART shares. Zacks Investment Research downgraded shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Citigroup downgraded shares of Integra Lifesciences from a “buy” rating to a “neutral” rating and increased their price objective for the company from $64.00 to $66.00 in a report on Monday, July 2nd. BidaskClub downgraded shares of Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. Oppenheimer reaffirmed a “buy” rating and set a $74.00 price objective on shares of Integra Lifesciences in a report on Wednesday, July 25th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $59.00 price objective on shares of Integra Lifesciences in a report on Wednesday, July 25th.

Shares of NASDAQ IART opened at $61.96 on Wednesday. Integra Lifesciences has a 1 year low of $41.51 and a 1 year high of $67.50. The firm has a market cap of $5.61 billion, a P/E ratio of 31.77, a PEG ratio of 2.03 and a beta of 0.57. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.60. The firm had revenue of $366.20 million for the quarter, compared to the consensus estimate of $368.08 million. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The firm’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 earnings per share. On average, research analysts anticipate that Integra Lifesciences will post 2.4 EPS for the current year.

In other news, Director Stuart Essig sold 31,353 shares of the stock in a transaction dated Tuesday, July 17th. The shares were sold at an average price of $63.50, for a total value of $1,990,915.50. Following the completion of the sale, the director now directly owns 1,450,272 shares in the company, valued at $92,092,272. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Glenn Coleman sold 8,916 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the completion of the sale, the vice president now owns 16,795 shares of the company’s stock, valued at $1,058,085. The disclosure for this sale can be found here. Insiders sold 111,140 shares of company stock valued at $7,054,647 over the last quarter. Company insiders own 5.10% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Zeke Capital Advisors LLC acquired a new stake in shares of Integra Lifesciences in the second quarter valued at about $204,000. We Are One Seven LLC raised its position in shares of Integra Lifesciences by 4,497.1% in the first quarter. We Are One Seven LLC now owns 3,218 shares of the life sciences company’s stock valued at $178,000 after buying an additional 3,148 shares during the last quarter. Eagle Boston Investment Management Inc. acquired a new stake in shares of Integra Lifesciences in the second quarter valued at about $223,000. Coldstream Capital Management Inc. acquired a new stake in shares of Integra Lifesciences in the first quarter valued at about $207,000. Finally, World Asset Management Inc acquired a new stake in shares of Integra Lifesciences in the second quarter valued at about $261,000. Institutional investors and hedge funds own 84.41% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Terms to Better Understand Call Options

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.